schliessen

Filtern

 

Bibliotheken

CCNB1 is a prognostic biomarker for ER+ breast cancer

Identification of effective prognostic biomarkers and targets are of crucial importance to the management of breast cancer. CCNB1 (also known as CyclinB1) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCN... Full description

Journal Title: Medical Hypotheses September 2014, Vol.83(3), pp.359-364
Main Author: Ding, Kun
Other Authors: Li, Wenqing , Zou, Zhiqiang , Zou, Xianzhi , Wang, Chengru
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0306-9877 ; E-ISSN: 1532-2777 ; DOI: 10.1016/j.mehy.2014.06.013
Link: https://www.sciencedirect.com/science/article/pii/S0306987714002485
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_mehy_2014_06_013
title: CCNB1 is a prognostic biomarker for ER+ breast cancer
format: Article
creator:
  • Ding, Kun
  • Li, Wenqing
  • Zou, Zhiqiang
  • Zou, Xianzhi
  • Wang, Chengru
subjects:
  • Medicine
ispartof: Medical Hypotheses, September 2014, Vol.83(3), pp.359-364
description: Identification of effective prognostic biomarkers and targets are of crucial importance to the management of breast cancer. CCNB1 (also known as CyclinB1) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNB1 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNB1 was closely associated with hormone therapy resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, using CCNB1-Drug interaction network, we demonstrated the interactions between CCNB1 and several available cancer drugs. Overall, we suggest that CCNB1 is a biomarker for the prognosis of ER+ breast cancer and monitoring of hormone therapy efficacy. It is also...
language: eng
source:
identifier: ISSN: 0306-9877 ; E-ISSN: 1532-2777 ; DOI: 10.1016/j.mehy.2014.06.013
fulltext: fulltext
issn:
  • 0306-9877
  • 03069877
  • 1532-2777
  • 15322777
url: Link


@attributes
ID1233418255
RANK0.06999999
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_mehy_2014_06_013
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_mehy_2014_06_013
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAOAW
17AAQFI
18ABBQC
19ABFNM
20ABGSF
21ABMZM
22ABYKQ
23ABZDS
24ACDAQ
25ACRLP
26ADUVX
27AEHWI
28AEKER
29AEVXI
30AFKWA
31AFTJW
32AFXIZ
33AGHFR
34AGRDE
35AGUBO
36AGYEJ
37AHHHB
38AIKHN
39AITUG
40AJBFU
41AJOXV
42AJRQY
43AJUYK
44ALCLG
45AMFUW
46ANZVX
47BLXMC
48BNPGV
49DOVZS
50EO8
51EO9
52EP2
53EP3
54FDB
55FGOYB
56FIRID
57FNPLU
58G-Q
59GBLVA
60HEA
61HMK
62HMO
63J1W
64KOM
65LCYCR
66OAUVE
67OGGZJ
68P-8
69P-9
70PC.
71Q38
72R2-
73RPZ
74SAE
75SCC
76SDF
77SDG
78SDP
79SEL
80SES
81SEW
82SSH
83SSP
84SSU
85SSZ
86T5K
87Z5R
88~G-
pqid1556284426
galeid381164373
display
typearticle
titleCCNB1 is a prognostic biomarker for ER+ breast cancer
creatorDing, Kun ; Li, Wenqing ; Zou, Zhiqiang ; Zou, Xianzhi ; Wang, Chengru
ispartofMedical Hypotheses, September 2014, Vol.83(3), pp.359-364
identifier
subjectMedicine
descriptionIdentification of effective prognostic biomarkers and targets are of crucial importance to the management of breast cancer. CCNB1 (also known as CyclinB1) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNB1 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNB1 was closely associated with hormone therapy resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, using CCNB1-Drug interaction network, we demonstrated the interactions between CCNB1 and several available cancer drugs. Overall, we suggest that CCNB1 is a biomarker for the prognosis of ER+ breast cancer and monitoring of hormone therapy efficacy. It is also...
languageeng
source
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0306987714002485$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Ding, Kun
1Li, Wenqing
2Zou, Zhiqiang
3Zou, Xianzhi
4Wang, Chengru
titleCCNB1 is a prognostic biomarker for ER+ breast cancer
description

Identification of effective prognostic biomarkers and targets are of crucial importance to the management of breast cancer. CCNB1 (also known as CyclinB1) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNB1 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNB1 was closely associated with hormone therapy resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, using CCNB1-Drug interaction network, we demonstrated the interactions between CCNB1 and several available cancer drugs. Overall, we suggest that CCNB1 is a biomarker for the prognosis of ER+ breast cancer and monitoring of hormone therapy efficacy. It is also...

subjectMedicine
general
0English
1Elsevier Ltd
210.1016/j.mehy.2014.06.013
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_mehy_2014_06_013
issn
00306-9877
103069877
21532-2777
315322777
rsrctypearticle
creationdate2014
addtitleMedical Hypotheses
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAOAW
17AAQFI
18ABBQC
19ABFNM
20ABGSF
21ABMZM
22ABYKQ
23ABZDS
24ACDAQ
25ACRLP
26ADUVX
27AEHWI
28AEKER
29AEVXI
30AFKWA
31AFTJW
32AFXIZ
33AGHFR
34AGRDE
35AGUBO
36AGYEJ
37AHHHB
38AIKHN
39AITUG
40AJBFU
41AJOXV
42AJRQY
43AJUYK
44ALCLG
45AMFUW
46ANZVX
47BLXMC
48BNPGV
49DOVZS
50EO8
51EO9
52EP2
53EP3
54FDB
55FGOYB
56FIRID
57FNPLU
58G-Q
59GBLVA
60HEA
61HMK
62HMO
63J1W
64KOM
65LCYCR
66OAUVE
67OGGZJ
68P-8
69P-9
70PC.
71Q38
72R2-
73RPZ
74SAE
75SCC
76SDF
77SDG
78SDP
79SEL
80SES
81SEW
82SSH
83SSP
84SSU
85SSZ
86T5K
87Z5R
88~G-
startdate20140901
enddate20140931
lsr40Medical Hypotheses, September 2014, Vol.83 (3), pp.359-364
doi10.1016/j.mehy.2014.06.013
citationpf 359 pt 364 vol 83 issue 3
lsr30VSR-Enriched:[galeid, pqid]
sort
titleCCNB1 is a prognostic biomarker for ER+ breast cancer
authorDing, Kun ; Li, Wenqing ; Zou, Zhiqiang ; Zou, Xianzhi ; Wang, Chengru
creationdate20140900
lso0120140900
facets
frbrgroupid7522086867231648429
frbrtype5
newrecords20190904
languageeng
topicMedicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Ding, Kun
1Li, Wenqing
2Zou, Zhiqiang
3Zou, Xianzhi
4Wang, Chengru
jtitleMedical Hypotheses
creationdate2014
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Ding
1Li
2Zou
3Wang
aufirst
0Kun
1Wenqing
2Zhiqiang
3Xianzhi
4Chengru
auinitK
auinit1K
au
0Ding, Kun
1Li, Wenqing
2Zou, Zhiqiang
3Zou, Xianzhi
4Wang, Chengru
atitleCCNB1 is a prognostic biomarker for ER+ breast cancer
jtitleMedical Hypotheses
risdate201409
volume83
issue3
spage359
epage364
pages359-364
issn0306-9877
eissn1532-2777
formatjournal
genrearticle
ristypeJOUR
abstract

Identification of effective prognostic biomarkers and targets are of crucial importance to the management of breast cancer. CCNB1 (also known as CyclinB1) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNB1 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNB1 was closely associated with hormone therapy resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, using CCNB1-Drug interaction network, we demonstrated the interactions between CCNB1 and several available cancer drugs. Overall, we suggest that CCNB1 is a biomarker for the prognosis of ER+ breast cancer and monitoring of hormone therapy efficacy. It is also...

pubElsevier Ltd
doi10.1016/j.mehy.2014.06.013
lad01Medical Hypotheses
date2014-09